Navigation Links
At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific Quality Control Test for Therapeutic Tissue Stem Cells
Date:3/14/2017

At the 6th Annual Clinical Trials Supply New England 2017 conference, held in Boston from March 8-9, James Sherley, M.D., Ph.D., director of Asymmetrex, led discussions that evaluated the quality of U.S. supplies of stem cells used in clinical trials compared to private stem cell clinics. Private stem cell clinics have been criticized for not employing research standards that are necessary to establish the therapeutic effectiveness of treatments with statistical confidence. In part because of this difference in practice, they are also often accused of making unproven claims about the effectiveness of their therapies.

Sherley presented comparisons of key operational elements to argue that, given good intent in both settings, the two different settings of stem cell treatments had both distinct and shared shortcomings. He noted, however, that the most significant shortcoming, which stem cell clinical trials and private stem cell clinics share, was perennially overlooked.

Based on the number of reported stem cell clinical trials and private stem cell clinics, Sherley estimated that close to a quarter-million patients in the U.S. now receive stem cell treatments each year. Though many of these occur within FDA-approved clinical trials, their number is dwarfed nearly 10 times by the number of treatments that occur in private stem cell clinics. It shocked the audience of clinical trial suppliers to learn that there was no stem cell quality control test performed for any of these many treatments.

Even for approved stem cell medicine treatments like bone marrow transplantation and umbilical cord blood transplant, there is no stem cell-specific quality control test available. Counts of total cells are made, but these do not adequately predict stem cell number or function. Biomarkers designated for tissue stem cells are also expressed by stem cells’ more abundant non-stem cell products. So, the biomarkers lack sufficient specificity to be used to count and monitor tissue stem cell function.

Without a quality control test for tissue stem cell number, stem cell treatments in all settings proceed without knowing the dose of treating tissue stem cells. This previously unavoidable therapeutic blind spot creates an instant treatment risk. It also precludes effective analyses to optimize treatment procedures, to compare different treatments, or to relate treatment outcomes to tissue stem cell dose. Without knowing stem cell dose, the interpretation of any stem cell treatment in terms of stem cells as the responsible agents is compromised.

In this context, Sherley announced briefly to attendees that Asymmetrex’s new AlphaSTEM Test for counting adult tissue stem cells and providing data on their viability and tissue cell renewal function represented the needed first quality control test for tissue stem cell treatments, whether in clinical trials, in private stem cell clinics, or approved therapies. In particular, he indicated that both stem cell treatment patients and progress in stem cell medicine would benefit from existing clinical trial supply companies developing into future private stem cell clinic supply companies to insure the quality of stem cell treatment preparations. Sherley said that, of course, their partnership with Asymmetrex to implement its new stem cell-specific quality control test was an all around best solution for accelerating progress in stem cell transplantation medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14146903.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting
2. BioDelivery Sciences to Present at the 29th Annual ROTH Conference
3. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
4. CytRx to Present at the 29th Annual ROTH Conference
5. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
6. Origin Agritech to Present at 29th Annual ROTH Conference on March 15, 2017
7. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
8. WuXi NextCODE to Present at 37th Annual Cowen and Company Healthcare Conference
9. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
10. Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
11. LabRoots to Host the 2nd Annual Precision Medicine Virtual Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... HOLLOWAY AMERICA, a stainless steel ... packaging event PACK EXPO International in Las Vegas from September 25 to 27. ... At this year’s PACK EXPO at the Last Vegas Convention Center, HOLLOWAY representatives ...
(Date:9/22/2017)... ... September 22, 2017 , ... The Academy of Model ... 28 and 29, 2017, to promote AMA’s programs, member services, and the model ... hobbies, including but not limited to model aviation and other RC activities. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar ... executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City Garage ... full range of manufacturing and business services to its Residents. , Vixiar ...
(Date:9/21/2017)... , ... (PRWEB) September 21, 2017 , ... ... international scientific and technical congress to review the latest knowledge on these products, ... prestigious international speakers will discuss the impact of Biostimulants on Plant Nutrition, Abiotic ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
Breaking Biology News(10 mins):